Oorsprong van het eerstegraads netwerk van Andrew H. Chang

EntiteitType entiteitIndustrie
Public Company Biotechnology 18

Grafiek van bedrijven verbonden in de tweede graad

Connectie in verschillende bedrijven

Bedrijven verbonden met Andrew H. Chang via zijn persoonlijke netwerk

OndernemingSectorGelieerde personenHoofdpost
AMGEN INC. Pharmaceuticals: Major

John Smither

Derek Maclean

Chief Administrative Officer

Corporate Officer/Principal

GT BIOPHARMA, INC. Pharmaceuticals: Major

Shawn Cross

Chief Executive Officer

CYCLO THERAPEUTICS, INC. Biotechnology

Shawn Cross

Director/Board Member

Pharmaceuticals: Major

Helen Kim

Charles Olson

Corporate Officer/Principal

Corporate Officer/Principal

IMUNON, INC. Biotechnology

Carolyn Finkle

General Counsel

Investment Banks/Brokers

Graham Cooper

Shawn Cross

Corporate Officer/Principal

Analyst-Equity

Investment Banks/Brokers

Shawn Cross

Analyst-Equity

Investment Banks/Brokers

Shawn Cross

Corporate Officer/Principal

ANTHERA PHARMACEUTICALS, INC. Pharmaceuticals: Major

Charles Olson

Chief Tech/Sci/R&D Officer

KYTHERA BIOPHARMACEUTICALS INC Pharmaceuticals: Major

Douglas A. Rich

John Smither

Chief Operating Officer

Director of Finance/CFO

NGM BIOPHARMACEUTICALS, INC. Biotechnology

Helen Kim

Charles Olson

Consultant / Advisor

Corporate Officer/Principal

College/University

David Lamond

Undergraduate Degree

University of California, Los Angeles College/University

Shawn Cross

Undergraduate Degree

University of Toronto College/University

Carolyn Finkle

Tahir Mahmood

Graduate Degree

Graduate Degree

University of California, Davis College/University

Randall J. Mrsny

Charlene Banard

Doctorate Degree

Undergraduate Degree

University of California, Santa Barbara College/University

Charles Olson

Brandon Hants

Graduate Degree

Undergraduate Degree

University of Iowa College/University

Bittoo Kanwar

Graduate Degree

Pharmaceuticals: Major

Helen Kim

Randall J. Mrsny

Director/Board Member

Founder

College/University

Shawn Cross

Corporate Officer/Principal

RELYPSA INC Pharmaceuticals: Major

Derek Maclean

Corporate Officer/Principal

PROTAGONIST THERAPEUTICS, INC. Biotechnology

Bittoo Kanwar

Chief Tech/Sci/R&D Officer

Investment Banks/Brokers

Shawn Cross

Corporate Officer/Principal

Miscellaneous Commercial Services

David Lamond

Director/Board Member

KITE PHARMA INC Biotechnology

Helen Kim

John Smither

Private Equity Investor

Director of Finance/CFO

Columbia Business School College/University

Shawn Cross

Masters Business Admin

Duke University School of Law College/University

David Lamond

Graduate Degree

ASSEMBLY BIOSCIENCES, INC. Pharmaceuticals: Major

Graham Cooper

Helen Kim

Director of Finance/CFO

Director/Board Member

UNITY BIOTECHNOLOGY, INC. Biotechnology

Graham Cooper

Douglas A. Rich

John Smither

Director/Board Member

Chief Operating Officer

Director of Finance/CFO

BIOPLUS ACQUISITION CORP. Financial Conglomerates

Shawn Cross

Director/Board Member

Pharmaceuticals: Major

Charles Olson

President

Medical Specialties

David Lamond

Director/Board Member

Financial Conglomerates

David Lamond

President

QUINCE THERAPEUTICS, INC. Biotechnology

David Lamond

Chairman

Medical Specialties

David Lamond

Director/Board Member

Data Processing Services

David Lamond

Director/Board Member

Ubuntu Pathways

David Lamond

Director/Board Member

LUCIRA HEALTH, INC. Medical Specialties

David Lamond

Chairman

Inquis Clinical Research Ltd.

David Lamond

Director/Board Member

Biotechnology

David Lamond

Director/Board Member

Pharmaceuticals: Major

David Lamond

Director/Board Member

Miscellaneous Commercial Services

David Lamond

Director/Board Member

Statistieken

Internationaal

Verenigde Staten 43
Canada 3
Frankrijk 3
Verenigd Koninkrijk 2

Sectoraal

Health Technology 23
Finance 11
Consumer Services 10
Technology Services 3
Commercial Services 3

Operationeel

Director/Board Member 60
Corporate Officer/Principal 44
Independent Dir/Board Member 20
Director of Finance/CFO 15
Undergraduate Degree 14
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU